BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38798793)

  • 1. Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis.
    Adrianzen-Herrera D; Giorgio K; Walker RF; Sparks AD; Gergi M; Zakai NA; Lutsey PL
    Res Pract Thromb Haemost; 2024 May; 8(4):102418. PubMed ID: 38798793
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bleeding risk in patients with multiple myeloma treated for venous thromboembolism: a MarketScan analysis.
    Adrianzen-Herrera D; Lutsey PL; Giorgio K; Walker RF; Zakai NA
    Res Pract Thromb Haemost; 2023 Jan; 7(1):100024. PubMed ID: 36873562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different strategies for pharmacological thromboprophylaxis for lower-limb immobilisation after injury: systematic review and economic evaluation.
    Pandor A; Horner D; Davis S; Goodacre S; Stevens JW; Clowes M; Hunt BJ; Nokes T; Keenan J; de Wit K
    Health Technol Assess; 2019 Dec; 23(63):1-190. PubMed ID: 31851608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thromboprophylaxis patterns, risk factors, and outcomes of care in the medically ill patient population.
    Mahan CE; Fisher MD; Mills RM; Fields LE; Stephenson JJ; Fu AC; Spyropoulos AC
    Thromb Res; 2013 Nov; 132(5):520-6. PubMed ID: 24080150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
    Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of anticoagulant choice on hospitalized bleeding risk when treating cancer-associated venous thromboembolism.
    Zakai NA; Walker RF; MacLehose RF; Adam TJ; Alonso A; Lutsey PL
    J Thromb Haemost; 2018 Dec; 16(12):2403-2412. PubMed ID: 30240508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
    Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interventions for implementation of thromboprophylaxis in hospitalized patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Diendéré G; Piché A; Filion KB; Klil-Drori AJ; Douketis JD; Emed J; Roussin A; Tagalakis V; Morris M; Geerts W
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD008201. PubMed ID: 29687454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interventions for implementation of thromboprophylaxis in hospitalized medical and surgical patients at risk for venous thromboembolism.
    Kahn SR; Morrison DR; Cohen JM; Emed J; Tagalakis V; Roussin A; Geerts W
    Cochrane Database Syst Rev; 2013 Jul; (7):CD008201. PubMed ID: 23861035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
    Di Nisio M; Porreca E; Otten HM; Rutjes AW
    Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thromboembolism Incidence and Risk Factors in Multiple Myeloma After First Exposure to Immunomodulatory Drug-Based Regimens.
    Patel JN; Robinson M; Jagosky M; Slaughter D; Arnall J; Jandrisevits E; Matusz-Fisher A; Atrash S; Paul B; Bhutani M; Voorhees P; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):188-198.e2. PubMed ID: 33339769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM group.
    Frenzel L; Decaux O; Macro M; Belhadj-Merzoug K; Manier S; Touzeau C; Leleu X; Frère C; Lecompte T; Perrot A; Avet-Loiseau H; Moreau P; Chalayer E
    Thromb Res; 2024 Jan; 233():153-164. PubMed ID: 38064842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair.
    Forster R; Stewart M
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD004179. PubMed ID: 27027384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Event rates and risk factors for venous thromboembolism and major bleeding in a population of hospitalized adult patients with acute medical illness receiving enoxaparin thromboprophylaxis.
    Gal GL; Agnelli G; Darius H; Kahn SR; Owaidah T; Rocha AT; Zhai Z; Khan I; Djoudi Y; Ponomareva E; Cohen AT
    Eur J Intern Med; 2024 Mar; 121():48-55. PubMed ID: 38030465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The risk of venous thromboembolism in surgically treated hip fracture: A retrospective cohort study of 5184 patients.
    Beauchamp-Chalifour P; Belzile ÉL; Michael R; Langevin V; Gaudreau N; Normandeau N; Bédard L; Pelet S
    Orthop Traumatol Surg Res; 2022 Feb; 108(1):103142. PubMed ID: 34775033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving rates of venous thromboembolism prophylaxis in multiple myeloma patients on immunomodulatory drugs through a pharmacy-based system.
    Parnes A; Leblebjian H; Hamilton J; Smith S; Laubach J; Berliner N
    J Oncol Pharm Pract; 2022 Mar; 28(2):421-424. PubMed ID: 33611974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of venous thromboembolism and bleeding after major surgery for ovarian cancer: standard in-hospital versus extended duration of thromboprophylaxis.
    Wiegers HMG; Schaafsma M; Guman NAM; Zelisse HS; Mulder FI; Middeldorp S; van Es N; Mom CH
    J Thromb Haemost; 2023 Feb; 21(2):294-302. PubMed ID: 36700503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism.
    Robertson L; Yeoh SE; Ramli A
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011088. PubMed ID: 29244199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer.
    Carrier M; Khorana AA; Moretto P; Le Gal G; Karp R; Zwicker JI
    Am J Med; 2014 Jan; 127(1):82-6.e1. PubMed ID: 24384102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.